An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Phase 1
18 Years
N/A
18 Years
N/A
Not Enrolling
Both
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Both
Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis
Trial Information
An Exploratory Pharmacogenomic Study of Monotherapy Erbitux in Subjects With Metastatic Non Small Cell Lung Carcinoma
Inclusion Criteria:
- Measurable disease tumor available for biopsies
- Life expectancy of at least 3 months
Exclusion Criteria:
- Known or documented brain metastases prior to Cetuximab therapy
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Prediction of response to Erbitux with non small cell lung cancer
Principal Investigator
Bristol-Myers Squibb
Investigator Role:
Study Director
Investigator Affiliation:
Bristol-Myers Squibb
Authority:
United States: Food and Drug Administration
Study ID:
CA225-065
NCT ID:
NCT00207116
Start Date:
September 2005
Completion Date:
March 2006
Related Keywords:
- Carcinoma, Non-Small-Cell Lung
- Neoplasm Metastasis
- Metastatic Non Small Cell Lung Cancer
- Neoplasms
- Carcinoma
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms
- Neoplasm Metastasis
Name | Location |
|---|---|
| Local Institution | Newark, Delaware |
